Three-Drug Regimen Beneficial for High-Risk Cytogenetic Myeloma Subgroup

Treatment with carfilzomib, lenalidomide, and dexamethasone improved the poor prognosis associated with high-risk cytogenetic abnormalities of multiple myeloma.

Source: CancerNetwork - August 4, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news